Next Generation Sequencing (NGS) is a powerful, flexible, and indispensable biological tool that is used in several areas of biological study. NGS technologies help in generating genome-wide sequence data in a couple of days. These technologies are highly parallelized allowing to sequence thousands to millions of molecules at the same time. The main advantage of these platforms is determination of the sequenced data from amplified single DNA fragments, avoiding the need for cloning of DNA fragments.
NGS has large number of applications, enabling rapid technological advances across several fields in biological science. The technology has enabled researchers to gain significant knowledge in public health studies and epidemiology, to sequence viruses and bacteria and help detect causes that may contribute to virulence. Furthermore, in gene expression research, next generation sequencing of RNA replace microarray analysis, allowing researchers to see RNA expression sequence. This RNA sequencing can provide information on entire transcriptome in one analysis, irrespective of any previous knowledge of genetic sequence.
The global next generation sequencing market was valued at US$ 5.6 billion in 2017 and is expected to witness a robust CAGR of 18.1% over the forecast period (2017–2025).
Rising demand for early detection of cancer and infectious diseases to drive growth of the NGS market
The chances of successful treatment increase when cancer and infectious diseases are detected at the early stage. One of the major factors that drive growth of the next generation sequencing market is the rising prevalence of cancer and other infectious diseases. According to the World Health Organization (WHO), in 2012, new cases of cancer was around 14 million and the incidence is estimated to increase to 70% by 2030.
As per statistics published by National Cancer Institute (NCI), in 2016, 1,685,210 new cases of cancer were diagnosed in the U.S. alone. In 2015, WHO reported 8.8 million deaths occurred due to cancer. According to American Cancer Society (ACS), in 2017, around 161,360 cases of prostate cancer were reported in the U.S alone. ACS, in 2015, also reported 4.5 million new cancer cases in China and the number is expected to increase to 7.6 Mn by 2020. Morbidity cases in tuberculosis, salmonella, and meningococcal disease was as high as 90,000 in the U.S. in 2016. Therefore, increasing demand for early diagnosis of cancer and infectious diseases, to aid in better outcome, is in turn expected to aid in growth of the market over the forecast period.
Increasing demand for DNA testing
Demand for DNA testing is increasing, due to advancements in whole genome and exome sequencing procedures, faster results and cost effectives of the process as compared to genotyping based DNA microarray. In December, 2014, the first commercial sequencer, MinIon, using Nanopore technology was introduced by Oxford Nanopore Technologies. The sequencer identifies DNA by measuring the changes in the electrical conductivity generated DNA strands passed through biological pore. This technology enabled the detection of outbreaks such as Zika virus. Furthermore, GenapSys, a U.S.-based developer of DNA sequencing technologies for applied genomic testing, introduced GENIUS sequencer, which can sequence DNA anywhere.
Next Generation Sequencing Market – Key Players
Key players in the next generation sequencing market include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., BioMerieux S.A., F. Hoffmann-La Roche Ltd, Qiagen N.V., Illumina, Inc., Oxford Nanopore Technologies, and Beijing Genomics Co. Ltd.
Get HOLISTIC Request Sample Copy Of Next Generation Sequencing Business Report: https://www.coherentmarketinsights.com/insight/request-sample/158